How Clay Siegall Has Supported The Advancement Of Cancer Research

Cancer is one of the diseases that have attracted a lot of activity from different professionals, who seek to deliver a solution to the menace to allow those affected to easily access treatment and quality treatment for that matter. Many companies have invested in this space to allow the development of technologies that are powerful and reliable in the treatment of cancer. Among professionals who have invested their time developing the cancer research industry, Clay Siegall has helped to bring together experts through Seattle Genetics, which has managed to unveil unique methods of treating the disease that do not affect the healthy cells of the patient.

Seattle Genetics pioneered the development of the ADC Technology, which allows patients to receive treatment without the worry of destroying healthy cells. The uniqueness of this technology comes in the sense that it allows experts to channel the waves on only those cells that are affected. Its adoption has been rising at a fast pace and several partnerships were signed to further develop the technology to offer specialized care to severely sick patients. Clay Siegall is confident in the development and growth of the technology and has also supported the adoption of ADCETRIS, which is a drug pipeline developed by Seattle Genetics to offer treatment to cancer patients.

About Clay Siegall

Clay Siegall is the founder and President of Seattle Genetics, a company that has championed cancer research for many years. He prides himself in bringing together a team of experts, who have helped Seattle Genetics to come up with technologies that are today supporting the treatment of cancer. As the Chief Executive Officer of Seattle Genetics, Clay Siegall has earned a reputation in the industry for calling for support from various agencies to advance research.

His educational background can be traced back to the Maryland University, where he pursued a degree in Zoology. He then proceeded to the Washington University for a PhD in Genetics. His effort has seen him receive several awards and recommendations to work with leading organizations. Clay Siegall is an author of over 70 publications, which have addressed clinical science and cancer research.

Leave a Reply